American College of Rheumatology

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.

A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.

In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.

In this video interview, Dr. Edigin talks about the importance of outpatient care in reducing hospitalizations for SLE flare.

Nathan den Broeder, MSs, shares the findings of his study at the ACR 2021 Convergence.

Research presented by Dr. Jing Cui at ACR 2021 Convergence identified significant risk factors for systemic lupus erythematosus in a risk prediction model study.

Research results shows that while overall hospitalization for SLE flare decreased, it increased among African American patients.

Dr. Jing Cui speaks about how she examined lifestyle and environmental factors as well as genetic risk to assess risk of systemic lupus erythematosus.

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

Favorable phase 2 results with the TYK2 inhibitor for psoriatic arthritis at ACR 2020 coincided with announced positive phase 3 trial results for psoriasis.

A secukinumab researcher explains why the practice may become the "next stethoscope" of medicine.

New findings show a unique series of markers could indicate particular black SLE patient risks.

A real-world study shows the therapy was slightly more efficacious for biologic-naive PsA patients.

A systematic review suggests patients taking immunosuppressive therapy may not be at as heightened risk of infection as previously thought.

An interview with a study author on the promising findings, and the use of ultrasonography in assessing psoriatic arthritis treatment.

Children hospitalized from the condition face a 14-fold increased risk of MACE.

The world is suddenly fixed on the field's most promising agents for an unprecedented virus. It's created a unique situation for specialists to collaborate.

The common rheumatic drug was found in a cohort analysis to be linked to greater regional TB outbreaks.

Less than 2% of surveyed families with rheumatic-disease children had reported a COVID-19 case in the early pandemic—and even fewer had physician-confirmed symptoms.